Meet One-on-One with… Johnson & Johnson California Innovation Center

May 2 2013

Congratulations! You have been approved to attend a one-on-one meeting with J&J California Innovation Center . To secure your time slot please register by choosing the desired ticket above. After receiving confirmation of your registration you will be notified of your meeting time slot.

10:30am | Registration & Networking  
11:00am | Presentation & Q&A  
11:45pm | Lunch & Networking
12:30pm | Optional Tours of Janssen Labs 
12:30pm-3:30pm |
One-on-one Meetings

Program Overview
The Johnson & Johnson California Innovation Center , focuses on identifying early-stage (pre-clinical proof-of-concept) innovation at academic institutions, start-up biotech companies and venture capital firms, and provides integrated capabilities to scout, evaluate, fund and onboard new science. The California Innovation Center is one of four Johnson & Johnson innovation centers with the goal to advance transformative healthcare solutions that deliver value and improve people’s lives around the world. Each center has broad deal-making capabilities, with flexibility to adapt deal structures, which enables innovators looking for partnerships access to a broad range of expertise and resources. Co-located in the Johnson & Johnson California Innovation Center is the Johnson & Johnson Development Corporation (JJDC) that provides venture capital for investment in external opportunities aligned with business strategies of The Johnson & Johnson Family of Companies. Since its inception in 1973, JJDC has been among the top-tier health care venture capital companies investing in and developing new businesses that create leading technologies, products, and services.  


Members from the Johnson & Johnson California Innovation Center and JJDC team will screen applicants and be in attendance on May 2nd to present on how to partner with Johnson & Johnson. Leaders from all areas of the life science industry are encouraged to apply today!


Adam Keeney, Ph.D. | Vice President, Head of Transactions, Johnson & Jonson Innovation Center California
Adam Keeney heads the Transactions group within the Johnson & Jonson Innovation Center - a novel approach to accelerate early innovation and enhance opportunities for collaboration and investment across J&J's healthcare businesses. Located in Menlo Park, CA, the West Coast Innovation Center will serve as a regional hub focused on identifying early-stage innovations, establishing novel collaborations and enhancing speed of development. The innovation center houses science and technology experts as well as local deal-making capabilities, with flexibility to adapt deal structures to match early-stage opportunities (defined as before clinical proof of concept). Dr. Keeney has a PhD in Neuropharmacology from the University of Nottingham, UK. After his post doc studies, Dr. Keeney joined H. Lundbeck A/S in Copenhagen (Denmark) working in the Neuroscience Drug Discovery group. While at Lundbeck, Dr. Keeney moved to lead the Scientific Licensing team within Business Development. Dr. Keeney joined the J&J Pharmaceutical Business Development group in 2004 and has held numerous roles with increasing responsibility, most recently as Vice President and Head of Cardiovascular & Metabolism Licensing.

Jeff Calcagno, M.D. | Principal, Venture Investments, Johnson & Johnson Development Corporation
Jeff Calcagno, Principal, Venture Investments, joined Johnson & Johnson Development Corporation (JJDC) in 2013. He is based in Silicon Valley, California. Dr. Calcagno came to J&J in 2011 and held roles in the Corporate Office of Science & Technology and the California Innovation Center. He has over two decades of healthcare and business experience: as a clinician, management consultant, research analyst, entrepreneur, and venture investor. Dr. Calcagno began his business career as a management consultant at McKinsey & Company. He later served as a healthcare research analyst at JP Morgan Hambrecht & Quist. As an entrepreneur, he ran corporate development and operations for WIDCOMM, a technology company acquired by Broadcom, and served as CFO & CBO for Vela Pharmaceuticals, a venture-backed drug development company. From 2006 to 2010 he was a Principal & Kauffman Fellow at Scale Venture Partners, a venture fund with over $1B under management. Dr. Calcagno graduated Phi Beta Kappa in Biology from Harvard College and earned an MD from Harvard Medical School, where he was a Rotary International Ambassadorial Scholar. He completed his medical-psychiatric internship and psychiatry residency at UCLA’s Neuropsychiatric Institute, served as program chief resident, and was awarded and completed a clinical neuropharmacology fellowship.

Asish K. Xavier, Ph.D. | Vice President, Venture Investments, Johnson & Johnson Development Corporation
Asish Xavier, Vice President, Venture Investments, joined Johnson & Johnson Development Corporation (JJDC) in 2004. He is based in Silicon Valley, California. Dr. Xavier previously worked in business development at BioRexis Pharmaceutical, Inc., which was acquired by Pfizer in 2007. While at BioRexis, he assisted the company in raising a $30 million second round of financing. Dr. Xavier has worked in business development at Structural GenomiX, Inc., acquired by Eli Lilly in 2008, and was a project leader at Message Pharmaceuticals, Inc. Dr. Xavier received a PhD from the University of Houston and a Master of Business Administration from the Wharton School of the University of Pennsylvania, where he graduated with honors. He received a Bachelor of Technology in Chemical Engineering from the Indian Institute of Technology, Kanpur, India. Dr. Xavier was also a postdoctoral research Fellow in the Department of Chemistry at Johns Hopkins University.